Article

EYP-1901: A look at DAVIO and PAVIA clinical trial updates

Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.

Video transcript

Note: This transcript has been lightly edited for clarity.

Jay S. Duker, MD: Hello, I'm Jay Duker. I'm the Chief Operating Officer of EyePoint Pharmaceuticals. I'd like to talk to you today about our lead product in the pipeline, EYP-1901.

EYP-1901 is a small-molecule tyrosine kinase inhibitor called vorolanib, which is in our proprietary Durasert insert. The Durasert insert that we're using is bioerodible. Our Phase 1 study was completed several months ago. It was called the DAVIO trial, and it enrolled 17 patients with previously treated wet age-related macular degeneration to 4 dosing cohorts. This was a single intravitreal injection done in the doctor's office. There was no control group. There was no reinjection of EYP-1901 during the study.

The primary results of any Phase 1 study is safety and our safety profile was quite good. We had no ocular SAEs [serious adverse events]. We had no drug-related systemic SAEs. The ocular AEs [adverse events] were generally mild and due to the injection and cleared without any sequelae. From an efficacy perspective, we showed stable visual acuity in OCTs through 1 year. Another look at efficacy would be the reduction in treatment burden. In other words, how many injections were the patients getting prior to EYP-1901 versus after. We had over a 70% reduction in treatment burden over the entire year of the study.

The rescue free rate at 4 months was up to 76%. At 6 months, it was up to 53% and almost one-third of the eyes went the full year without any supplement anti-VEGF injection. Subgroup analysis showed that eyes that entered the study dry with no excess fluid did exceptionally well with a 92% reduction in treatment burden and over 50% of the eyes going to full year without supplement.

We're very excited about the program. We've initiated a Phase 2 DAVIO2 trial in wet macular degeneration that enrolled the first patient 2 months ago. Last week we enrolled our first patient in the PAVIA trial, which is using EYP-1901 in nonproliferative diabetic retinopathy. I look forward to sharing results of those trials in the future. Thank you.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.